Table 3. Subgroup analysis for cefixime susceptibility rates.
| Subgroup type | Susceptibility rate (95%CI) | No. of the NG isolates | No. of the studies | Heterogeneity | χ2 test | ||
| I2 (%) | P-value | χ2 | P-value | ||||
| Population a | |||||||
| Men (RS) | 96.5 (94.6–97.8) | 868 | 5 | 0.405 | <0.001 | - | - |
| mix | 99.9 (99.9–99.9) | 76415 | 7 | 0.480 | <0.001 | 1341.499 | <0.001 |
| Patients | 99.8 (99.7–99.9) | 11330 | 6 | 0.383 | 0.022 | 6776.778 | <0.001 |
| FSWs | 99.7 (94.8–100.0) | 147 | 1 | - | - | - | - |
| Sex workers | 98.4 (78.9–99.9) | 30 | 1 | - | - | - | - |
| Young men | 99.7 (98.3–99.8) | 168 | 1 | - | - | - | - |
| Continents | |||||||
| Asia (RS) | 97.4 (95.7–98.1) | 1650 | 9 | 0.397 | <0.001 | - | - |
| Europe | 99.0 (98.1–99.4) | 3080 | 6 | 0.389 | 0.017 | 669.637 | <0.001 |
| North America | 99.9 (99.9–99.9) | 84005 | 4 | 0.375 | 0.054 | 183.740 | <0.001 |
| Africa | 99.5 (96.4–99.9) | 223 | 2 | <0.001 | 0.367 | 3.987 | 0.046 |
| Japan or other countries | |||||||
| Other Asian countries (RS) | 99.3 (97.3–99.8) | 339 | 3 | <0.001 | 0.416 | - | - |
| Japan | 93.8 (91.6–95.4) | 1311 | 6 | 0.468 | <0.001 | 6.069 | 0.014 |
| Other continents | 99.9 (99.8–99.9) | 87366 | 12 | 0.466 | <0.001 | 3.768 | 0.052 |
| Collection period | |||||||
| Before or during 2003 (RS) | 99.8 (99.8–99.9) | 78558 | 9 | 0.485 | <0.001 | - | - |
| After 2003 | 99.0 (98.6–99.3) | 10202 | 13 | 0.460 | <0.001 | 198.597 | <0.001 |
| Unknown | 99.3 (95.3–99.9) | 198 | 2 | <0.001 | 0.283 | - | - |
| Overall | 99.8 (99.7–99.8) | 88958 | 21 | 0.481 | <0.001 | - | - |
a
Study population: FSWs (female sex workers); men (men with urethritis); mix (male and female patients), patients (patients whose gender was not identified); young men (young men with discharge); Sex workers (sex workers whose gender was not identified). RS: Reference Subgroup (the subgroups compared with others by χ2 test).